Covid-19 Vaccination in Adolescents and Children

Overview

Objectives To assess the reactogenicity, measure the adaptive immune responses and track the long-term immune memory in healthy children and adults as well as pediatric patients receiving the COVID-19 vaccines-BNT162b2, CoronaVac-chosen by the Hong Kong Government; to compare the reactogenicity and immunogenicity across the vaccines used for these children and adults. Hypothesis to be tested The safety profile and the magnitude and durability of immune responses to the COVID-19 vaccines in children are non-inferior to those in adults. Design and subjects A single-site, comparative nonrandomised clinical trial for 450 healthy individuals or patients under 18 years old and one or both healthy parents and unrelated adults to receive one of COVID-19 vaccines by intramuscular injection (and intradermal injection) Instruments Mobile app for subjects to record adverse effects, enzyme-linked immunosorbent assay, plaque reduction neutralization assay, luciferase immunoprecipitation system assay and flow cytometry. Interventions BNT162b2 and CoronaVac, by intramuscular or intradermal route Main outcome measures Types and frequencies of adverse effects within 7 days, and changes and peaks of antibody levels and antigen-specific memory T cell responses for 3 years.

Full Title of Study: “To Compare the Reactogenicity and Immunogenicity of Recommended COVID-19 Vaccines in Young Adolescents and Children in Hong Kong”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 31, 2025

Interventions

  • Biological: Tozinameran
    • mRNA vaccine developed by BioNTech against COVID-19
  • Biological: CoronaVac
    • Inactivated virus vaccine developed by SinoVac against COVID-19, intramuscular
  • Biological: CoronaVac, intradermal
    • Inactivated virus vaccine developed by SinoVac against COVID-19, intradermal

Arms, Groups and Cohorts

  • Experimental: BNT162b2 (adult/adolescent)
    • BNT162b2, tozinameran by Fosun/BioNTech Intramuscular injection (or intradermal for immunocompromised patients; or by graded challenge with history of non-severe allergy to PEG-containing drugs) 30ug/0.3ml per dose 3 doses, or 4 for immunocompromised patients; or 1/2 dose for patients with prior COVID-19
  • Experimental: CoronaVac (intramuscular)
    • CoronaVac by SinoVac Intramuscular injection 3ug/0.5ml per dose 3 doses, or 4 for immunocompromised patients; or 1/2 dose for patients with prior COVID-19
  • Experimental: CoronaVac (intradermal)
    • CoronaVac by SinoVac Intradermal injection 3ug/0.5ml per dose 3 doses, or 4 for immunocompromised patients; or 1/2 dose for patients with prior COVID-19
  • Experimental: BNT162b2 (paediatric)
    • BNT162b2, tozinameran by Fosun/BioNTech Intramuscular injection (for immunocompromised patients only) 10ug/0.1ml per dose 4 doses for immunocompromised patients

Clinical Trial Outcome Measures

Primary Measures

  • Adverse reactions
    • Time Frame: 7 days post-doses 1, 2 and 3 (and 4)
    • Percentage of occurrence, types, duration and severity of adverse reactions occurring within 7 days
  • Binding antibody response
    • Time Frame: 1 month post-dose 1, and 1, 6, 18, and 36 months post-dose 3 (and 2 weeks after dose 4)
    • Geometric mean levels of SARS-CoV2 S and S-RBD-specific binding antibody and related markers as determined by Enzyme-linked Immunosorbent Assay
  • Neutralizing antibody response
    • Time Frame: 1 month post-dose 1, and 1, 6, 18, and 36 months post-dose 3 (and 2 weeks after dose 4)
    • Geometric mean levels and geometric mean fold rise of SARS-CoV2 neutralizing antibodies as determined by plaque reduction neutralization assay and surrogate assays
  • T cell response
    • Time Frame: 1 month post-dose 1, and 1, 6, 18, and 36 months post-dose 3 (and 2 weeks after dose 4)
    • Geometric mean percentage of CD4 and CD8 T cells specific to SARS-CoV2 S (and N and M) protein

Secondary Measures

  • Vaccine breakthrough
    • Time Frame: Throughout the study period, until 36 months post-dose 3/4
    • Incidence of COVID-19 in participants throughout study period as self-reported or as determined by Luciferase Immunoprecipitation Systems assay/ELISA
  • Adverse events
    • Time Frame: Throughout the study period, until 36 months post-dose 3/4
    • Percentage of occurrence, types, duration and severity of adverse events and severe adverse events throughout study period
  • Binding anti-N antibody response
    • Time Frame: 1 month post-dose 1, and 1, 6, 18, and 36 months post-dose 3 (and 2 weeks after dose 4)
    • Geometric mean levels and geometric mean fold rise of SARS-CoV2 N-specific binding antibody as determined by Enzyme-linked Immunosorbent Assay in Arm C participants receiving CoronaVac

Participating in This Clinical Trial

Inclusion Criteria

1. informed consent from the parents or a legally acceptable representative for an underage participant 2. biological parents of students enrolled in the trial or unrelated healthy adults 3. ability to adhere to the follow-up schedules 4. willingness to report reactogenicity daily for 7 days post dose 1, 2 and 3 (and 4) proactively 5. willingness to receive that vaccine available for that particular recruitment period (as student-parent pair, if applicable) 6. good past health, including pre-existing clinically stable disease, such as paediatric or immune disorders 7. prior COVID-19 (for COVID-19 survivor subgroup) Exclusion Criteria:

1. reported pregnancy or breastfeeding

Gender Eligibility: All

Minimum Age: 0 Years

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • The University of Hong Kong
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yu Lung Lau, MD, Principal Investigator, The University of Hong Kong

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.